Simulations Plus Inc (SLP) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... |

Between; align-items: center; flex-wrap: wrap;">

Published: Friday, April 4, 2025 · 7:01 AM | Updated: Friday, April 4, 2025 · 7:01 AM

📊 434 views

SHARE

🗝️ Key Points

Release Date: April 03, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q & A Highlights Q: Can you discuss the software organic revenue growth and the decline in the fee renewal rate to 90%?.
A: The software organic growth was 8% this quarter, excluding the Pro-ficiency software contribution.

Release Date: April 03, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Total revenue increased by 23% year-over-year, with a 5% organic growth excluding contributions from new business units.
Software revenue grew by 16%, driven by strong performance in the Quantitative Systems Pharmacology (QSP) business unit, which saw an 89% revenue surge.
The company maintained a high software customer renewal rate of 90% based on fees, indicating strong customer retention.
Simulations Plus Inc (SLP, Financial) ended the quarter with $21.4 million in cash and short-term investments, maintaining a strong financial position with no debt.
The company reaffirmed its fiscal year 2025 guidance, expecting total revenue between $90 million to $93 million, indicating confidence in continued growth.

Negative Points

Services revenue, although up 34%, was flat on an organic basis, with clients delaying project initiations to the second half of the year.
Gross margin decreased to 59% from 72% in the prior-year quarter, primarily due to increased costs in software and services.
Net income for the quarter decreased to $3.1 million from $4 million in the previous year, with diluted EPS dropping from $0.20 to $0.15.
The renewal rate based on fees declined from 94% to 90%, impacted by a large customer renewal that was delayed until the third quarter.
The operating environment remains challenging, with customers taking a cost-conscious approach to spending, affecting the pace of service project initiations.

Q & A Highlights

Q: Can you discuss the software organic revenue growth and the decline in the fee renewal rate to 90%?
A: The software organic growth was 8% this quarter, excluding the Pro-ficiency software contribution. The renewal rate dropped to 90% due to one large account renewal that occurred shortly after the quarter ended. This was a significant renewal, impacting the fee-based renewal rate more than the account-based rate. – Shawn O’Connor, CEO

Q: How do you reconcile strong software growth with clients being slow to start new service projects?
A: Our software provides essential infrastructure for clients’ modeling and simulation efforts, which remains a priority even in cost-constrained environments. Clients are more cautious with service budgets, leading to slower project initiations. However, we are seeing contracts signed for projects scheduled later in the year. – Shawn O’Connor, CEO

Q: Can you provide more details on the recent $5 million contract win in the Medical Communications segment?
A: The contract is with an existing client and involves support for multiple drugs. It will contribute to revenue in the second half of fiscal 2025 and extend into calendar 2025. This reflects our strategy of cross-selling and expanding services with existing clients. – Shawn O’Connor, CEO

Q: How does the recent FDA disruption impact biosimulation adoption?
A: While the FDA’s internal disruptions are challenging, the drug development approval process is primarily fee-funded and less impacted by federal funding cuts. The adoption of biosimulation is driven by its efficiency and cost benefits, and we do not expect a significant slowdown in its adoption. – Shawn O’Connor, CEO

Q: What are your expectations for fiscal 2026 given current macroeconomic conditions?
A: The market environment will be a significant factor. Our software business is well-insulated and should continue to grow. The service side’s performance will depend on market stabilization and a return to normal development activity flows. – Shawn O’Connor, CEO

For the complete transcript of the earnings call, please refer to the full earnings call transcript.